Lupin’s alliance partner Concord gets approval for Mycophenolate Mofetil Tablets
6th Aug 2020

Lupin’s alliance partner Concord Biotech (Concord) has received approval from the United States Food and Drug Administration (USFDA) for Mycophenolate Mofetil Tablets USP, 500 mg, to market a generic version of CellCept Tablets of Roche Palo Alto LLC (Roche). Mycophenolate Mofetil Tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets USP, 500 mg (RLD: CellCept) had an annual sales of approximately $96 million in the U.S. 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.